Back to results
US 8,410,093 B2Granted
Cycloalkyl substituted pyrimidinediamine compounds and their uses
AssigneeRigel Pharmaceuticals, Inc.
InventorsHui Li, Ankush Argade, Rajinder Singh, Sambaiah Thota, David Carroll, Kin Tso, Vanessa Taylor, John McLaughlin, Vadim Markovtsov
Life of this patent
Estimating the term…
Abstract
The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
Claims20
A compound according to structural formula (I):
- or an active salt or N-oxide thereof, wherein:
- R2 is an optionally substituted, heteroaryl, or heteroarylalkyl group;
- R4 is a saturated or unsaturated, bridged or unbridged cycloalkyl ring including an R7 substituent, with the proviso that when the cycloalkyl ring is a saturated bridged cycloalkyl, or an unsaturated bridged or unbridged cycloalkyl, this R7 substituent is optional;
- R5 is selected from hydrogen, an optionally substituted lower alkyl and a group selected from the group consisting of —CN, —NC, —NO2, halo, (C1-C3) haloalkyl, (C1-C3) perhaloalkyl, (C1-C3) fluoroalkyl, (C1-C3) perfluoroalkyl, —CF3, (C1-C3) haloalkoxy, (C1-C3) perhaloalkoxy, (C1-C3) fluoroalkoxy, (C1-C3) perfluoroalkoxy, —OCF3, OC(O)Ra, —C(O)ORa, —C(O)CF3, and —C(O)CF3;
- R7 is an amide or an ester group,
- wherein each Ra is independently selected from hydrogen, lower alkyl, lower cycloalkyl, (C6-C14) aryl, phenyl, naphthyl, (C7-C20) arylalkyl and benzyl.
3 more elements
Dependencies are inferred from the claim text.